期刊
EMBO MOLECULAR MEDICINE
卷 7, 期 6, 页码 689-691出版社
WILEY
DOI: 10.15252/emmm.201505160
关键词
-
资金
- NHLBI NIH HHS [HL098053, R01 HL066012, P01 HL098053, R01 HL115014, HL125208, HL066012, U01 HL125208, HL115014] Funding Source: Medline
Elevated pulmonary arterial pressure in patients with pulmonary hypertension (PH) is mainly caused by increased pulmonary vascular resistance (PVR), due primarily to sustained pulmonary vasoconstriction and excessive pulmonary vascular remodeling. According to the current classification, PH has been classified into five categories based on etiology (Simonneau etal, ). Among them, group 1 or pulmonary arterial hypertension (PAH) is a rare but progressive and deadly disease affecting similar to 1-10 per 1 million people. Despite expanding treatment options to ameliorate patients' symptoms, PAH remains a devastating disease with a poor long-term prognosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据